Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)-Reference-Cited by-同舟云学术

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Published:2020-04 Issue:4 Volume:31 Page:495-500
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Metaxas Y.,Früh M.,Eboulet E.I.,Grosso F.,Pless M.,Zucali P.A.,Ceresoli G.L.,Mark M.,Schneider M.,Maconi A.,Perrino M.,Biaggi-Rudolf C.,Froesch P.,Schmid S.,Waibel C.,Appenzeller C.,Rauch D.,von Moos R.

Funder

PharmaMar

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference24 articles.

1. Malignant mesothelioma;Robinson;Lancet,2005

2. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Baas;Ann Oncol,2015

3. Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma;Kostron;Eur J Cardiothorac Surg,2016

4. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial;Gregorc;Lancet Oncol,2018

5. Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma;Ceresoli;Cancer Treat Rev,2015

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rehabilitation for Functioning and Quality of Life in Patients with Malignant Pleural Mesothelioma: A Scoping Review;Current Oncology;2024-07-30

2. Comprehensive Pulmonary Rehabilitation for Patients with Malignant Pleural Mesothelioma: A Feasibility Pilot Study;Cancers;2024-05-26

3. A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas;Current Treatment Options in Oncology;2024-02

4. Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment—Progresses in Their Use in Combined Cancer Therapy;Molecules;2024-01-09

5. Immunotherapy vs. Chemotherapy in Subsequent Treatment of Malignant Pleural Mesothelioma: Which Is Better?;Journal of Clinical Medicine;2023-03-27